Skip to main content
OpenTrials
Completed

NCT Number: NCT00717262

Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects

The purpose of this study is to evaluate the safety, activity and pharmacokinetics of a new investigational drug (HQK-1001) in healthy human volunteers. This study will also evaluate if there are differences in these parameters when HQK-1001 is administered in a fed versus a fasted state.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Charles River Clinical Services Northwest

Tacoma, Washington, 98403, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male or female
  • Between the ages of 18 and 45 years old
  • Able and willing to give informed consent
  • Able to comply with all study procedures
  • If female, must not be of childbearing potential or must agree to use one or more of the following forms of contraception during screening and throughout the study: hormonal (i.e., oral, transdermal, implant or injection); double barrier (i.e., condom, diaphragm with spermicide); intrauterine device (IUD); vasectomized partner (6 months minimum); or abstinence
  • Male subjects must also agree to use one or more of the above forms of birth control for either themselves or their partner, as appropriate, throughout the course of the study
  • Not receiving medications within the 2 weeks before the first dose of study medication, except for multivitamins and contraception
  • Complete blood count (CBC) with white blood cell (WBC) count hemoglobin, hematocrit, reticulocyte count and platelet count within normal range for the testing facility or not clinically significant
  • Serum ferritin level > 50 ng/ml in Cohort 1
  • Serum ferritin level > 30 mg/ml in Cohorts 2, 3, 4 and 5
  • Serum chemistry values, coagulation tests and urinalysis values within the normal range for the testing facility or not clinically significant
  • Negative urine test for substances of abuse including marijuana, cocaine, opiates, and methadone

Exclusion criteria

  • Prior participation in HQP 2007-001
  • Clinically significant abnormal vital signs
  • Blood donation within 2 months of study medication administration
  • Blood transfusion within 3 months of study medication administration
  • An acute febrile illness or upper respiratory tract illness within 72 hours prior to administration of study medication
  • Received another investigational agent within 4 weeks before administration of study medication
  • Receiving any other investigational agent during this study
  • Any acute or chronic disease (e.g., history of hepatitis B or C or HIV-1)
  • Heart disease including an abnormal electrocardiogram, clinical significant, (ECG) or cardiac arrhythmia
  • History of neurological disease, such as a seizure disorder
  • Currently pregnant or breast feeding a child
  • A smoker in the past 12 months
  • Body Mass Index (BMI) >33 kg/m2

Treatment and study plan

HQK-1001

Drug

HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.

Placebo

Drug

Matching placebo capsules administered once a day, orally, for 14 days.

Primary outcomes

  1. Safety as assessed by (1) adverse events, (2) laboratory values (3) vital signs (4) physical exam

    Time frame: 41 days

Secondary outcomes

  1. Pharmacokinetics assessed by plasma drug concentration levels

    Time frame: 15 days

  2. Pharmacodynamics assessed by red blood cell production and induction of fetal hemoglobin

    Time frame: 41 days

  3. Comparison of safety, PK and PD under fed versus fasting conditions

    Time frame: 41 days

  4. Comparison of safety and PK when oral iron is administered with HQK-1001.

    Time frame: 41 days

Sponsors and collaborators

Lead sponsor

HemaQuest Pharmaceuticals Inc.

Industry

Registry information

Official study title

A Phase 1, Double-Blind, Placebo Controlled, Repeat-Dose Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Volunteers

Important dates

Study start
2008
Primary completion
2008
Study completion
2008
First posted
Jul 17, 2008
Registry last updated
Jan 16, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.